Skip to Content
UW Health SMPH
American Family Children's Hospital
Brad S. Kahl, MD close
Brad S. Kahl, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Brad S. Kahl, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Kahl is an Associate Professor of Medicine at the University of Wisconsin. He is the Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies for the University of Wisconsin Carbone Cancer Center. He received his medical degree from Tufts University, where he was elected AOA. He completed all post-graduate training at the University of Wisconsin. Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group.



UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Tufts University School of Medicine, Boston, MA


Madison Magazine Top Docs 2014

Best Doctors® in America 2014

Best Doctors® in America 2013

Madison Magazine Top Docs 2012

Best Doctors® in America 2011

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.


Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.


Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of ECOG study 4402, Rituximab Extended Schedule or Retreatment Trial (RESORT).

PubMed Articles
Cheson BD Brugger W Damaj G Dreyling M Kahl B Kimby E Ogura M Weidmann E Wendtner CM Zinzani PL . Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2015 Nov 23;:1-17
[PubMed ID: 26592922]
Diefenbach CS Li H Hong F Gordon LI Fisher RI Bartlett NL Crump M Gascoyne RD Wagner H Jr Stiff PJ Cheson BD Stewart DA Kahl BS Friedberg JW Blum KA Habermann TM Tuscano JM Hoppe RT Horning SJ Advani RH . Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov;171(4):530-8
[PubMed ID: 26343802]
Fenske TS Shah NM Kim KM Saha S Zhang C Baim AE Farnen JP Onitilo AA Blank JH Ahuja H Wassenaar T Qamar R Mansky P Traynor AM Mattison RJ Kahl BS . A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. Cancer. 2015 Oct 1;121(19):3465-71
[PubMed ID: 26079295]
Witzig TE Hong F Micallef IN Gascoyne RD Dogan A Wagner H Jr Kahl BS Advani RH Horning SJ . A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br J Haematol. 2015 Sep;170(5):679-86
[PubMed ID: 25974212]
Roberts AW Advani RH Kahl BS Persky D Sweetenham JW Carney DA Yang J Busman TB Enschede SH Humerickhouse RA Seymour JF . Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015 Sep;170(5):669-78
[PubMed ID: 25942994]
Kahl BS Gordon LI Dreyling M Gascoyne RD Sotomayor EM . Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2015 Sep;56(9):2505-11
[PubMed ID: 25944379]
Wang ML Blum KA Martin P Goy A Auer R Kahl BS Jurczak W Advani RH Romaguera JE Williams ME Barrientos JC Chmielowska E Radford J Stilgenbauer S Dreyling M Jedrzejczak WW Johnson P Spurgeon SE Zhang L Baher L Cheng M Lee D Beaupre DM Rule S . Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45
[PubMed ID: 26059948]
Barr PM Li H Spier C Mahadevan D LeBlanc M Ul Haq M Huber BD Flowers CR Wagner-Johnston ND Horwitz SM Fisher RI Cheson BD Smith SM Kahl BS Bartlett NL Friedberg JW . Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404
[PubMed ID: 26077240]
Swinnen LJ Li H Quon A Gascoyne R Hong F Ranheim EA Habermann TM Kahl BS Horning SJ Advani RH . Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015 Jul;170(1):56-65
[PubMed ID: 25823885]
Advani RH Hong F Fisher RI Bartlett NL Robinson KS Gascoyne RD Wagner H Jr Stiff PJ Cheson BD Stewart DA Gordon LI Kahl BS Friedberg JW Blum KA Habermann TM Tuscano JM Hoppe RT Horning SJ . Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10;33(17):1936-42
[PubMed ID: 25897153]
Nazeef M Kahl BS . Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. Curr Treat Options Oncol. 2015 Jun;16(6):29
[PubMed ID: 25975443]
Rajguru S Kahl BS . Mantle cell lymphoma-management in evolution. Chin Clin Oncol. 2015 Mar;4(1):8
[PubMed ID: 25841715]
Wagner LI Zhao F Hong F Williams ME Gascoyne RD Krauss JC Advani RH Go RS Habermann TM Leach JW O'Connor B Schuster SJ Cella D Horning SJ Kahl BS . Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015 Mar 1;33(7):740-8
[PubMed ID: 25605841]
Kahl BS Hong F Williams ME Gascoyne RD Wagner LI Krauss JC Habermann TM Swinnen LJ Schuster SJ Peterson CG Sborov MD Martin SE Weiss M Ehmann WC Horning SJ . Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1;32(28):3096-102
[PubMed ID: 25154829]
Fletcher CD Kahl BS . Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014 Oct;55(10):2228-40
[PubMed ID: 24286262]
Casulo C Vose JM Ho WY Kahl B Brunvand M Goy A Kasamon Y Cheson B Friedberg JW . A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol. 2014 Sep;154(1):37-46
[PubMed ID: 24928323]
Rajguru S Kahl BS . Emerging therapy for the treatment of mantle cell lymphoma. J Natl Compr Canc Netw. 2014 Sep;12(9):1311-8; quiz 1318
[PubMed ID: 25190697]
Rajguru S Kristinsdottir T Eickhoff J Peterson C Meyer CM Traynor AM Kahl BS . Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol. 2014 Aug;12(8):509-15
[PubMed ID: 25356575]
Kahl BS Spurgeon SE Furman RR Flinn IW Coutre SE Brown JR Benson DM Byrd JC Peterman S Cho Y Yu A Godfrey WR Wagner-Johnston ND . A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29;123(22):3398-405
[PubMed ID: 24615778]
Brown JR Byrd JC Coutre SE Benson DM Flinn IW Wagner-Johnston ND Spurgeon SE Kahl BS Bello C Webb HK Johnson DM Peterman S Li D Jahn TM Lannutti BJ Ulrich RG Yu AS Miller LL Furman RR . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7
[PubMed ID: 24615777]